"Solid start to 2026 – strong growth in CERAMENT® G in the US and improved cash flow." Torbjörn Sköld, CEO

JANUARY - MARCH 2026

• Net sales increased by 14 percent (31 percent at constant exchange rates) and amounted to SEK 324.0 million (283.5).
• The US segment reported a sales growth of 16 percent (35 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 9 percent (16 percent at constant exchange rates).
• The gross margin amounted to 92.2 percent (92.6).
• The adjusted operating result amounted to SEK 84.9 million (39.7). The reported operating result amounted to SEK 72.2 million (29.6).
• Earnings per share before dilution were SEK 0.81 (0.16).
• Earnings per share after dilution were SEK 0.80 (0.16).

EVENTS DURING THE QUARTER

• In February, the first US-based clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in the area of bone infection resulting from trauma was published.
• In March, the first US clinical case series with focus on infection prevention for trauma patients was published.

EVENTS AFTER THE PERIOD

• The US CMS proposes improved reimbursement for the use of CERAMENT G, in complex orthopaedic infection surgery, and more specific identification codes for CERAMENT G and CERAMENT® V from 2027 onwards. The final decision is expected in late summer.
• The Company also communicated that CMS proposes NTAP for CERAMENT V as of October 1, 2026, provided that the US FDA grants the Company's De Novo application no later than April 30, 2026. If an FDA approval is granted at a later date, the Company plans to submit a new NTAP application with a possible compensation supplement from October 1, 2027.